The Central Role of CD8+ T Cells in Cancer Immunotherapy: From Functional Remodeling to Clinical Translation
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 30 September 2026 | Viewed by 99
Special Issue Editor
Interests: tumor microenvironment; T cell dysfunction; immunometabolism
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
As central effectors of cancer immunotherapy, CD8+ T cells determine therapeutic outcomes through their functional status. Recent advances have revealed that T-cell differentiation, exhaustion, and memory formation are governed by intricate epigenetic and metabolic programs.
This Special Issue focuses on the functional remodeling, metabolic regulation, phenotypic plasticity, and tumor microenvironment crosstalk of CD8+ T cells, as well as their translational applications in immunotherapy. It aims to integrate recent advances in basic research and clinical practice, providing novel insights for optimizing immunotherapeutic strategies and improving cancer patient outcomes.
We invite original research and timely reviews that bridge fundamental immunology with translational applications, aiming to establish new paradigms for T-cell-based therapies in oncology.
Prof. Dr. Shengjun Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CD8+T cells
- T cell exhaustiont
- metabolic reprogramming
- epigenetic regulation
- tumor microenvironmen
- immune checkpoint blockade
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
